Illumina, Inc. (ticker: ILMN, exchange: NASDAQ Global Select Market (.O))
News Release -
Illumina to Present at Upcoming Investment Conferences in September
SAN DIEGO--(BUSINESS WIRE)--Aug. 28, 2008--Illumina, Inc.
(NASDAQ:ILMN) today announced that the Company will webcast its
presentations at two upcoming investment conferences in September
Illumina will webcast its presentation at the Thomas Weisel Health
Care Conference in Boston, Massachusetts on September 4, 2008. The
live webcast is scheduled to begin at 3:50 p.m. ET. Illumina will also
webcast its presentation at the UBS Global Life Sciences Conference in
New York, New York on September 23, 2008. The live webcast is
scheduled to begin at 8:00 a.m. ET. Both conferences will feature an
overview of Illumina by Christian Henry, Senior Vice President and
Chief Financial Officer, followed by a question and answer session.
Both live webcasts can be accessed under the "Corporate/Investor
Information" tab of Illumina's web site at www.illumina.com.
Illumina (www.illumina.com) is a leading developer, manufacturer,
and marketer of next-generation life-science tools and integrated
systems for the large-scale analysis of genetic variation and
biological function. Using our proprietary technologies, we provide a
comprehensive line of products and services that currently serve the
sequencing, genotyping, and gene expression markets, and we expect to
enter the market for molecular diagnostics. Our customers include
leading genomic research centers, pharmaceutical companies, academic
institutions, clinical research organizations, and biotechnology
companies. Our tools provide researchers around the world with the
performance, throughput, cost effectiveness, and flexibility necessary
to perform the billions of genetic tests needed to extract valuable
medical information from advances in genomics and proteomics. We
believe this information will enable researchers to correlate genetic
variation and biological function, which will enhance drug discovery
and clinical research, allow diseases to be detected earlier, and
permit better choices of drugs for individual patients.
"Safe Harbor" Statement under the Private Securities Litigation
Reform Act of 1995: this release may contain forward-looking
statements that involve risks and uncertainties. Among the important
factors that could cause actual results to differ materially from
those in any forward-looking statements are Illumina's ability (i) to
integrate effectively our recent acquisition of Solexa, Inc., (ii) to
develop and commercialize further our BeadArray(TM), VeraCode(R), and
Solexa(R) technologies and to deploy new sequencing, gene expression,
and genotyping products and applications for our technology platforms,
(iii) to manufacture robust microarrays and Oligator(R)
oligonucleotides, (iv) to integrate and scale our VeraCode technology,
together with other factors detailed in our filings with the
Securities and Exchange Commission including our recent filings on
Forms 10-K and 10-Q or in information disclosed in public conference
calls, the date and time of which are released beforehand. We disclaim
any intent or obligation to update these forward-looking statements
beyond the date of this release.
CONTACT: Illumina, Inc.
Maurissa Bornstein, 858-332-4055
Public Relations Manager
Peter J. Fromen, 858-202-4507
Sr. Director, Investor Relations
SOURCE: Illumina, Inc.